U.S. markets open in 6 hours 37 minutes
  • S&P Futures

    4,167.00
    -9.25 (-0.22%)
     
  • Dow Futures

    33,962.00
    -119.00 (-0.35%)
     
  • Nasdaq Futures

    14,029.50
    0.00 (0.00%)
     
  • Russell 2000 Futures

    2,247.00
    -12.00 (-0.53%)
     
  • Crude Oil

    63.00
    -0.13 (-0.21%)
     
  • Gold

    1,779.80
    -0.40 (-0.02%)
     
  • Silver

    25.91
    -0.19 (-0.75%)
     
  • EUR/USD

    1.1982
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.5730
    0.0000 (0.00%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3853
    +0.0014 (+0.10%)
     
  • USD/JPY

    108.5150
    -0.2680 (-0.25%)
     
  • BTC-USD

    56,731.91
    -60.71 (-0.11%)
     
  • CMC Crypto 200

    1,290.65
    -101.06 (-7.26%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Innovus Pharma Expands its Men's Health Franchise with the Addition of Exclusive Rights to Androferti(R) to Support Overall Male

Innovus Pharma Expands its Men's Health Franchise with the Addition of Exclusive Rights to Androferti(R) to Support Overall Male Reproductive Health and Sperm Quality for the U.S. and Canadian Market

SAN DIEGO, CA / ACCESSWIRE / January 28, 2015 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and vitality, announced today that it entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Androferti(R), a patented and clinically proven product to support male reproductive health and sperm quality, in the U.S. and Canada.

Androferti(R), has been shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and enhance spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperm ("REM")).

Androferti(R) is the only product clinically proven to increase the sperm quality and enhance spermatozoa quality as compared to other products where the claims are based on an ingredient used in such products.

"Androferti(R) is a great addition to our growing pipeline in men's health products. With our already existing retail and online infrastructure, we currently believe that we should be able to launch the product in Q2-Q3 of this year following claim clearance from the U.S. Food and Drug Administration," said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma.

"According to reports by IBIS World August 2014, the fertility market is estimate to be around $2 billion with a 2.5% yearly increase. With only 682 In-Vitro Fertility clinics in the U.S. we should be able to reach all of these clinics within a relatively short period of time," continued Dr. Damaj.

"We are excited to partner with Innovus Pharma on the commercialization of our product Androferti(R)," said Cesar Quintanilla, President & Chief Executive Officer of Q Pharma. Androferti(R)is a best seller in multiple European countries due to its proven clinical efficacy and we look forward to a successful launch of the product in the U.S. and Canada.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R), for the indication of penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R) and Vesele(R) for promoting sexual and cognitive health.

For more information, go to www.innovuspharma.com, www.zestra.com; www.myvesele.com; www.ejectdelay.com and www.sensumplus.com.

Innovus Pharma's Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to Androferti, to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Lynnette Dillen, EVP and CFO
ir@innovuspharma.com
858.964-5123

SOURCE: Innovus Pharmaceuticals, Inc.